Organs-on-chips Market Size (2023 - 2030)

The global organs-on-chips market size was valued at USD 9.6 million in 2022 and is expected to reach USD 46.5 million by 2030, growing with a CAGR of 36.8% during the foreseeable period.

Organ-on-chips is a 3D microfluidic structure chip that pretends a particular organ in the body besides its mechanics and physiological using a method from a computer chip manufacturing company that can perform processes like breathing, infection, and peristalsis.

Moreover, the organ-on-chips plays a vital role in drug discovery and research fields help in obtaining higher exactness for toxicity detection and testing to limit drug amount failing in clinical trials for humans.

The organ chip is made of a flexible polymer that is of computer memory stick size. The organ chip is a hollow micro-fluid channel for human organ-specific cells that is enclosed by the microenvironment of living organs.

Organ-on-chip contributes an extensive range of applications like phenotypic screening, diseases modeling, and patient organization. The organ-on-chip is used to control the behavior and cell moments and materials used by using channels, membranes, and chambers.

MARKET DRIVERS

The volume of organ failures is surging in the form of the heart, liver, lungs, and kidneys. The rising geriatric population results in organ failures which propels the market growth. The accumulating process of new drug development and the demand for personalized medicine accentuate the market growth across the foreseen period.

The Organ-on-chips has some applications like anti-aging research, access to personalized medicine, combat against cancer. Moreover, the funds and investments for research and development activities are increasingly impacting the market positively.

MARKET RESTRAINTS

However, mocking the highly complicated architecture of human organs is one factor restraining the organ-on-chips market.

Segment Analysis

Organs-on-chips Market - By Type:

• Liver

• Heart

• Lung

• Kidney

• Others

Based on the type, the lung organ-on-chip dominated the market in 2016. The segment continues to retain its dominance throughout the forecasted period.

The heart-on-chip segment is expected to account for considerable growth with the largest share due to the growing demand for effective treatment for heart disorders with the rising frequency of cardiovascular diseases. The segment can reproduce the mechanism of the heart and permit quick drug testing and medications.

Organs-on-chips Market - By Offerings:

• Products

• Services

Based on the offerings, the products segment is awaited to observe healthy growth due to its wide range of applications.

Organs-on-chips Market - By Application:

• Physiological Model Development
• Drug Discovery
• Toxicology Research

Based on the application, the drug discovery segment holds a notable share. The demand for diagnostic in-vitro methods for developing drugs in pharmaceutical companies and the rising tendency for substitutes to traditional cell culture methods help in driving the segment to grow further. 

Organs-on-chips Market - By End-User:

• Pharmaceutical & Biotechnology Companies
• Academic & Research Institutes
• Cosmetics Industry
• Other

Based on the end-user industry, the pharmaceutical and biotechnology companies segment holds the largest share in the market. Both the pharmaceutical and biotechnology companies invest highly in research and development activities. The biotechnology and pharmaceutical companies are highly adopting the organ-on-chips to achieve more success and to upgrade new drug substances. 

Regional Analysis

North America is expected to account for the largest share and to grow with the highest CAGR rate during the foreseen period. The region's largest share and the highest growth rate owes to the ease of availability of new and progressive organ-on-chips models. The appreciative government measures in terms of funds and programs for drug development along with growing research and development activities and the strong advent of major pharmaceutical companies bloom the market.

The U.S organ-on-chips market witnessed growth at considerable growth due to the attainability of novel and technologically developed organs-on-chips market. Appropriate infrastructure and favorable government measures for basic drug development and research augment the market growth. For example, the U.S FDA approved 5.6 USD billion to The Wyss Institute for testing its organ-on-chips technology advanced for estimation of drugs.

Europe is the second-largest region to have considerable growth in the organ-on-chips market. Factors like rising elderly people and the demand for regenerative medicine are on high rise propelling the market growth. Flying adoption of advanced technologies and growing investments by the pharmaceutical companies for drug discovery and the major appearance of leading firms providing a speedy growth in terms of revenue.

However, Asia-Pacific is expected to observe an astonishing development. Developing economies like India, Japan, and China provide diverse growth opportunities. For example, in May 2022, CN Bio made a strategic agreement with AXT for the distribution of organ-on-chips systems in the APAC region. The key players in the region who are involved in the manufacturing of organ-on-chips products are witnessing the upgrading regions to escalate the market impression influencing the Indian market growth.

China is predicted to be one of the quickest growing economies in the region.

The Indian organ-on-chips market is intended to grow at a noteworthy rate during the predicted period. The growth in India owes to the advancing healthcare industry and the growing expenses in the healthcare sector.

Latin America is likely to have steady and constant growth in the organs-on-chips market. The demand for personalized medication and enormous applications of the organs-on-chips over the pharmaceutical industry is creating growth opportunities for the market players.

The Middle East and Africa are anticipated to have a nascent and sluggish growth in the organs-on-chips market.

Major key players operating in the Organs-on-chips Market

1. Mimetas (Netherlands)

2. Emulate (US)

3. InSphero (Switzerland)

4. Ascendance Bio (US)

5. CN Bio (UK)

6. TissUse (Germany)

7. Kirkstall (UK)

8. HUREL (HUREL) (US)

9. SynVivo (US)

10. AxoSim (US)

11. Nortis (US).

COVID-19 Impact On Organs-on-chips Market

The sudden outbreak of the novel coronavirus (COVID-19) pandemic has originated in Wuhan, China, in December 2022. The severity of the pandemic crisis has affected many economies and industries due to temporary lockdowns, restrictions on travel. The shutdown of various industries and manufacturing plants was impacted negatively.

However, the demand for organs-on-chips has reduced because of the increasing COVID-19 cases. But, during the COVID-19 period, the organ-on-chip market is projected to witness quick and high growth. The market is one of the most promising growth when it comes to drug and vaccines development that is under clinical trials. 

For example, in March 2022, as a part of the WHO's Research and Development Blueprint response to the COVID-19, the emulate lung chip was used to provide preclinical insights into the efficiency of hydroxychloroquine for COVID-19. 

Recent Market Developments
•    On March 03, 2022, MIMETAS launched the first product release of its Assay Ready product line: OrganoPlate Caco-2. Caco-2 is a human colon adenocarcinoma cell line with a well-preserved barrier. MIMETAS is the leading player in Organ-on-chips technology.

•    On November 15, 2022, Emulate launched the Zoe-CM2 Culture Module. The Zoe-CM2 culture module is the second-generation instrument that is at the core of their Human Emulation System. 

•    On August 24, 2022, InSphero AG circulated as the company is making its proprietary, patented 96- and 384- microwell plates available for researchers permitting them to access the same plate technology.

•    On May 05, 2022, CN Bio has announced the expansion of their research collaboration. The expansion follows the success of CN Bio's and FDA's agreement